The software uses AI to identify large vessel occlusion strokes on computed tomography angiography imaging. Credit: Gerd Altmann from Pixabay.

Viz.ai has received CE mark to market its artificial intelligence (AI)-driven stroke care software, Viz LVO, in the European Economic Area.

The intelligent care coordination system links a variety of care teams, synchronises care and prioritises patients using its software suite. The suite can coordinate stroke care, lower time to treatment and enhance patient outcomes, clinical data shows.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Viz LVO leverages AI to identify suspected large vessel occlusion (LVO) strokes on computed tomography angiography (CTA) images.

It then notifies on-call stroke experts about the patients who could be treated in a standalone or multi-hospital setting.

Viz.ai co-founder and CEO Chris Mansi said: “Minutes matter when you’re having a stroke, which is why Viz.ai is dedicated to reducing time to treatment and improving patient outcomes through improved care coordination.

“The CE mark allows us to bring our leading AI software to the EU, significantly expanding the number of patients we can help get access to life-saving therapy.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

In a large, real-world multi-centre study, Viz LVO demonstrated a median time-to-notification of five minutes and 45 seconds across all trial centres.

Furthermore, the software had a sensitivity of 96% and specificity of 94% in detecting LVOs in 2,544 patients from 139 hospitals while utilising scanners from different companies.

The company noted that quicker triage with Viz LVO facilitates the detection and treatment of more people who require thrombectomy, which enhances patient outcomes and lowers long-term disability risks.

Stroke is the second common cause of mortality and a major cause of disability in adults in the European Union (EU). Viz.ai noted that only about 1.9% of patients get potentially lifesaving, less invasive endovascular procedure to remove blood clots.

Viz.ai received a de novo clearance for Viz LVO from the US Food and Drug Administration (FDA) in February 2018.

In July 2019, Medtronic agreed to distribute Viz.ai’s software across US centres.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact